Does sandostatin affect blood sugar levels?

Does Sandostatin affect blood sugar levels?

Sandostatin (octreotide) can raise or lower blood sugar. It slows the release of insulin and glucagon from the pancreas, so glucose control becomes less predictable. Patients with diabetes or those at risk for low blood sugar need closer monitoring when treatment begins.

What changes in blood sugar are most common?

High blood sugar occurs more often than low blood sugar. The drug reduces insulin secretion while glucagon is also suppressed, creating a net tendency toward hyperglycemia in many users. Low blood sugar is still possible, especially in people who already take insulin or sulfonylureas.

How long do the effects on glucose last?

Blood-sugar shifts appear within hours of an injection. With the long-acting depot form, the impact can persist for weeks, so dose adjustments or extra glucose checks may be needed throughout treatment.

Can Sandostatin be used safely in people with diabetes?

Yes, but therapy requires extra oversight. Doctors often adjust diabetes medicines or add glucose monitoring when octreotide starts. Blood-sugar logs help identify patterns so doses can be fine-tuned quickly.

Why do some patients see the opposite effect?

Individual responses vary. In certain tumors that secrete insulin, octreotide lowers insulin output and can raise blood sugar. In other tumors that drive hypoglycemia, the same drug can stabilize or even raise glucose. Baseline tumor type and existing diabetes medicines explain much of the difference.

When does the risk of low blood sugar peak?

Episodes of hypoglycemia are most likely shortly after the first few doses or after a dose increase. They are also more common in patients who eat irregularly or combine Sandostatin with other glucose-lowering drugs.

Are there alternatives that spare blood sugar?

Alternatives such as lanreotide or pasireotide share similar glucose effects. For symptom control without strong impact on insulin, non-somatostatin options like everolimus or sunitinib may be considered, though each carries its own metabolic profile.

DrugPatentWatch.com